Function of the Stem Cell Transcription Factor Sox2 in Prostate Cancer

干细胞转录因子 Sox2 在前列腺癌中的功能

• 批准号: 9228342
• 负责人: Donald James Vander Griend
• 金额: $ 32.32万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-01 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9228342
• 关键词: Adult; American; Androgen Antagonists; Androgen Receptor; Androgens; Basal Cell; Binding; Biological Markers; Cancer Etiology; Castration; Cell Death; Cell Proliferation; Cell Survival; Cells; ChIP-seq; Clinical; Data; Developmental Gene; Disease; Environment; Epigenetic Process; Epithelial Cells; FGF5 gene; Gene Chips; Gene Expression; Gene Targeting; Genes; Genetic Transcription; Goals; Growth; Indolent; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of prostate; Mediator of activation protein; Metastatic to; Neoplasm Metastasis; Oncogenes; Patients; Prostate; Prostatic Neoplasms; Receptor Signaling; Relapse; Resistance; Role; Seminal Vesicles; Signal Pathway; Stem cells; Tissues; Tumor-Derived; Tumorigenicity; Undifferentiated; Work; androgen deprivation therapy; cancer cell; cancer initiation; castration resistant prostate cancer; cell growth; embryonic stem cell; gene function; human embryonic stem cell; human tissue; improved; in vivo; knock-down; men; mortality; novel; pluripotency; prostate cancer cell; public health relevance; sex; targeted treatment; taxane; transcription factor; tumor; tumor initiation; tumor progression; tumorigenic

DESCRIPTION (provided by applicant): Prostate cancer is the most common non-cutaneous cancer and the second leading cause of cancer related mortalities among American men. For advanced prostate cancers, androgen deprivation therapy (ADT) has been the mainstay treatment for nearly 70 years. Malignant relapse of prostate cancer after ADT (commonly referred to as castration-resistant prostate cancer, or CRPC), however, is a significant clinical problem and new strategies are needed to improve patient survival. In contrast to the prostate, cancers arising in the seminal vesicle are exceedingly rare. To identify new genes and signaling pathways involved in prostate cancer initiation and progression we conducted an expression array analyses comparing normal prostate vs. seminal vesicle epithelial cells and identified Sox2 [SRY (sex determining region Y)- box 2] as one of many developmental genes that are highly expressed in adult prostate epithelial cells. Sox2 is an essential transcription factor for maintaining the survival and pluripotency of undifferentiated embryonic stem cells (ESCs), and has an emerging role as an epigenetic reprogramming factor and oncogene. The function of Sox2 in embryonic stem cells is well defined and requires other essential co-factors such as Oct4 and Nanog. In adult prostate tissues and tumors, however, such Sox2 transcriptional co-factors are not expressed, suggesting that Sox2 has unique, non-stem cell gene targets and functions within adult cells. Little is known, however, about the function and clinical impact of Sox2 expression in prostate cancer, and the relationship between Sox2 and the Androgen Receptor (AR) in metastatic, castration-resistant prostate cancer. The long term goal of this project is to elucidate the signaling pathways regulated by Sox2 which can be used to predict cancer progression and can be targeted for the treatment of advanced prostate cancers. The objective of this proposal is to define the mechanism of how Sox2 promotes cell survival and growth in an androgen-deprived environment. Our central hypothesis is that Sox2 functions as an oncogene by regulating a novel set of gene targets to promote cancer cell survival and proliferation, and not via mechanisms of inhibiting differentiation and promoting pluripotency. This mechanism of Sox2 function occurs via interaction with transcriptional co-regulators unique to adult epithelial cells, and not Oct4 or Nanog.

描述（由申请人提供）：前列腺癌是美国男性中最常见的非皮肤癌，也是癌症相关死亡的第二大原因。对于晚期前列腺癌，近70年来雄激素剥夺疗法（ADT）一直是主要治疗方法。然而，ADT后前列腺癌（通常称为去势抵抗性前列腺癌或CRPC）的恶性复发是一个重要的临床问题，需要新的策略来提高患者的生存率。与前列腺不同，发生在精囊的癌症非常罕见。为了鉴定参与前列腺癌发生和发展的新基因和信号通路，我们进行了表达阵列分析，比较了正常前列腺与精囊上皮细胞，并鉴定了Sox 2 [SRY（性别决定区Y）-框2]作为在成人前列腺上皮细胞中高度表达的许多发育基因之一。Sox 2是维持未分化胚胎干细胞（ESC）存活和多能性的必需转录因子，并且作为表观遗传重编程因子和癌基因具有新兴作用。Sox 2在胚胎干细胞中的功能是明确的，需要其他必要的辅助因子，如Oct 4和Nanog。然而，在成人前列腺组织和肿瘤中，这种Sox 2转录辅因子不表达，表明Sox 2在成人细胞内具有独特的非干细胞基因靶点和功能。然而，关于Sox 2在前列腺癌中表达的功能和临床影响，以及Sox 2和雄激素受体（AR）在转移性去势抵抗性前列腺癌中的关系，知之甚少。该项目的长期目标是阐明Sox 2调节的信号通路，可用于预测癌症进展，并可用于治疗晚期前列腺癌。该提案的目的是定义Sox 2如何在雄激素缺乏的环境中促进细胞存活和生长的机制。我们的中心假设是Sox 2作为癌基因通过调节一组新的基因靶点来促进癌细胞存活和增殖，而不是通过抑制分化和促进多能性的机制。Sox 2功能的这种机制是通过与成人上皮细胞特有的转录辅助调节因子相互作用而发生的，而不是Oct 4或Nanog。